Covid-19-Related Problems In Children May Be Treated With A New Drug |New Updates!
The SARS-CoV-2 virus, which causes COVID-19, causes an uncommon but serious illness in children. Scientists have discovered a promising therapeutic candidate that has the potential to save these children’s lives.
A mild or even asymptomatic case of COVID-19 can lead to a condition known as a multi-inflammatory syndrome in children (MIS-C), according to the study.
They added that MIS-C causes high fevers and a hyperinflammatory response that can harm many systems, including the heart, brain, and gastrointestinal organs.
The SARS-CoV-2 virus was shown to persist in the gut for weeks or months after infection in cases of MIS-C, according to a prior study conducted by researchers at Massachusetts General Hospital (MGH) and Brigham and Women’s Hospital (BWH) in the United States.
Small viral particles, such as the spike protein, can reach the bloodstream if SARS-CoV-2 is present in the stomach, resulting in infections such as COVID-19 and, in rare circumstances, the hyperinflammatory response that triggers MIS-C.
- After Over 3,000 Soldiers Were Cited for Not Receiving Covid-19 Vaccines, the Us Army Has Begun Expelling Those Who Refuse to Receive Them.
- A Federal Judge In The United States Has Blocked The Requirement That All Biden Government Employees Receive The Covid Vaccine | Viral News
- Protesting Covid Vaccination Regulations, Canadian Truckers Blocked An Us Border Route | Viral News
Working in tandem, we have demonstrated that COVID-19 virus particles that stay in the stomach long after the infection can trigger MIS-C,” stated senior author David Walt, who led the study published by Critical Care Explorations.
Following this critical discovery, we sought to test whether a medicine developed for celiac disease could help relieve symptoms in children with MIS-C,” stated Walt.
For the treatment of MIS-C, the researchers gave larazotide acetate to four very sick children, ranging in age from three to seventeen.
It has been shown that larazotide reduces the release of the zonulin, which can lead to increased intestinal permeability and a compromised mucosal barrier, the thick layer of mucus in the stomach.
Clinical outcomes were compared between children who received larazotide and steroids as well as intravenous immunoglobulin (IVIG) and those who got only steroids and IVIG.
According to the researchers, the children who received four daily oral doses of larazotide acetate had considerably faster gastrointestinal symptoms resolutions and a little shorter hospital stay.
The spike protein levels in the blood of children treated with larazotide declined significantly faster than those of children not treated with the medicine, clearing from the blood after one day compared to 10 days.
The researchers concluded that “these findings imply that larazotide may be a safe and useful adjuvant therapy for the treatment of MIS-C.”.
There is an urgent need for more clinical trials to determine the impact of larazotide on MIS-C.
If you want to learn more about the most recent news, go to our site by clicking here.